Is BLLN a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Share gains and menu expansion in prenatal screening, with revenue (ttm) at ~$397 million, up ~90% year over year. The bear case rests on illumina sued BillionToOne in the District of Delaware in May 2026 alleging infringement of three patents covering fetal fraction measurement and variant identification in mixed DNA samples, and the complaint targets the Unity products that supply most of the revenue, so an adverse outcome could mean royalties, an injunction, or a redesign of the core franchise. Analysts covering it are spread from $90.00 to $145.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Illumina sued BillionToOne in the District of Delaware in May 2026 alleging infringement of three patents covering fetal fraction measurement and variant identification in mixed DNA samples, and the complaint targets the Unity products that supply most of the revenue, so an adverse outcome could mean royalties, an injunction, or a redesign of the core franchise. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $90.00, -1.8% from the $91.65 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Share gains and menu expansion in prenatal screening. Unity is the revenue engine, at about $94.2 million in the second quarter of 2026 and up roughly 55% year over year, and the company has taken meaningful share in a US market long dominated by Natera. The most optimistic analyst target on BLLN is $145.00, +58.2% from the $91.65 price. That figure is only reachable if this thesis works close to its best case.

Illumina sued BillionToOne in the District of Delaware in May 2026 alleging infringement of three patents covering fetal fraction measurement and variant identification in mixed DNA samples, and the complaint targets the Unity products that supply most of the revenue, so an adverse outcome could mean royalties, an injunction, or a redesign of the core franchise. Revenue depends heavily on payer reimbursement decisions and on average selling price holding up, and a coverage change at a large commercial payer or a Medicare rate revision would show up directly in the growth rate without any change in test volume. Natera remains far larger in non-invasive prenatal testing and Guardant Health, Foundation Medicine, Tempus and Caris are entrenched in oncology liquid biopsy, so both franchises compete against companies with more scale and longer payer relationships. The valuation carries essentially no cushion: the stock traded at roughly 119 times trailing earnings before the August 2026 drop and still around 9 to 11 times forward revenue after it, which is why an in-line quarter produced a 39% single-day decline. Governance is concentrated, with Class B shares carrying 15 votes each and the two founders controlling roughly 64% of voting power at the time of the IPO, and the post-IPO lockup expired on May 5, 2026, with insider sales reported since. The most pessimistic published target is $90.00, -1.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

BillionToOne is a molecular diagnostics company whose DNA-counting platform powers the Unity prenatal screening tests and the Northstar oncology liquid biopsy line.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Share gains and menu expansion in prenatal screening) stalling in the reported numbers rather than in the narrative, the risk above (illumina sued BillionToOne in the District of Delaware in May 2026 alleging infringement of three patents covering fetal fraction measurement and variant identification in mixed DNA samples, and the complaint targets the Unity products that supply most of the revenue, so an adverse outcome could mean royalties, an injunction, or a redesign of the core franchise) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Two clinical franchises plus a small services line. Unity is a prenatal screen run from a maternal blood draw that covers chromosomal conditions, single-gene disorders, and fetal RhD and antigen status, and it produced about $94.2 million of second-quarter 2026 revenue. Northstar is the oncology line, including an 84-gene circulating tumor DNA panel for therapy selection and a treatment-monitoring assay, at about $13.7 million. Clinical trial support added roughly $1.5 million.

The second-quarter 2026 report on August 5 showed revenue of $109.4 million against roughly $111.6 million expected and non-GAAP earnings of $0.15 against roughly $0.19 modeled, and full-year guidance of $450 million to $465 million was reiterated rather than raised. Growth was still 64% year over year, but the stock had run to about $150 near its 52-week high, so an in-line quarter without an upward revision was enough to trigger a roughly 39% decline.

Yes, on both a GAAP and cash basis, which is unusual at this stage in diagnostics. Net income was about $8.1 million in the second quarter of 2026 and roughly $26 million across the first half, against a loss in the year-ago period. Trailing twelve-month net income was about $38 million and trailing free cash flow about $33 million. Full-year 2025 net income was only $2.9 million, so the profitability is recent and still thin relative to a $4.3 billion market value.